AIM: £5.04 (+0.24) | Nasdaq: $32.90 (+1.04)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Expanded Access
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Careers
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Expanded Access
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
Audit Committee – Terms of Reference
AIM Rule 26
Careers
Surufatinib at ESMO 2020
and SANET-ep & SANET-p results in The Lancet Oncology
Learn More
2020 Half-Year Results
Presentation Webcast & Call | Thursday, July 30, 2020
View Event Details
CNBC Street Signs
CEO Christian Hogg discusses plans for surufatinib U.S. NDA submission
Watch Interview
Corporate Presentation
Building a global science-focused biopharma from an established base in China
Download Presentation
The Lancet Oncology:
Osimertinib plus Savolitinib in EGFRm+, MET-amplified NSCLC
Read Abstract
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Innovation Platform
|
20 Sep 2020
Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
Innovation Platform
|
17 Sep 2020
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
Innovation Platform
|
4 Sep 2020
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Innovation Platform
|
3 Sep 2020
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China
Innovation Platform
|
24 Aug 2020
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020
Current Share Price
London AIM:HCM
£5.04
+0.24 | 25 Sep 2020 | 16:42
Nasdaq AIM:HCM
US$32.90
+1.04 | 25 Sep 2020 | 16:00
Note: 1 Nasdaq share = 5 AIM shares
Latest Presentations
21 Sep 2020
The Lancet Oncology: Surufatinib SANET-p phase 3 study
21 Sep 2020
The Lancet Oncology: Surufatinib SANET-ep phase 3 study
20 Sep 2020
ESMO2020: Surufatinib for patients with advanced pancreatic NET (SANET-p)
Latest Reports
Interim Report 2020
EN
Annual Report 2019 (with Form 20-F)
EN
Interim Report 2019
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More